Rhythm Pharmaceuticals, Inc. (RYTM): Price and Financial Metrics
GET POWR RATINGS... FREE!
RYTM POWR Grades
- Growth is the dimension where RYTM ranks best; there it ranks ahead of 36.93% of US stocks.
- The strongest trend for RYTM is in Stability, which has been heading down over the past 179 days.
- RYTM ranks lowest in Stability; there it ranks in the 2nd percentile.
RYTM Stock Summary
- RYTM's price/sales ratio is 82.01; that's higher than the P/S ratio of 97.16% of US stocks.
- As for revenue growth, note that RYTM's revenue has grown 4,239.48% over the past 12 months; that beats the revenue growth of 99.56% of US companies in our set.
- The volatility of RHYTHM PHARMACEUTICALS INC's share price is greater than that of 96.49% US stocks with at least 200 days of trading history.
- Stocks with similar financial metrics, market capitalization, and price volatility to RHYTHM PHARMACEUTICALS INC are BBI, ADCT, BCDA, LCTX, and FRSX.
- Visit RYTM's SEC page to see the company's official filings. To visit the company's web site, go to www.rhythmtx.com.
RYTM Valuation Summary
- RYTM's price/sales ratio is 95.9; this is 1709.43% higher than that of the median Healthcare stock.
- RYTM's price/sales ratio has moved NA NA over the prior 60 months.
Below are key valuation metrics over time for RYTM.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| RYTM | 2022-09-01 | 95.9 | 6.6 | -7.3 | -6.1 |
| RYTM | 2022-08-31 | 85.5 | 5.9 | -6.5 | -5.4 |
| RYTM | 2022-08-30 | 84.2 | 5.8 | -6.4 | -5.3 |
| RYTM | 2022-08-29 | 83.3 | 5.7 | -6.4 | -5.2 |
| RYTM | 2022-08-26 | 90.7 | 6.2 | -6.9 | -5.7 |
| RYTM | 2022-08-25 | 90.1 | 6.2 | -6.9 | -5.7 |
RYTM's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- RYTM has a Quality Grade of F, ranking ahead of 2.46% of graded US stocks.
- RYTM's asset turnover comes in at 0.004 -- ranking 418th of 681 Pharmaceutical Products stocks.
- EVOK, ATRA, and EVFM are the stocks whose asset turnover ratios are most correlated with RYTM.
The table below shows RYTM's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-09-30 | 0.004 | 0.728 | -0.232 |
| 2021-06-30 | 0.001 | 0.544 | -0.211 |
| 2021-03-31 | 0.000 | 0.886 | -0.196 |
| 2020-12-31 | 0.000 | NA | -0.922 |
| 2020-09-30 | 0.000 | NA | -0.718 |
| 2020-06-30 | 0.000 | NA | -0.784 |
RYTM Price Target
For more insight on analysts targets of RYTM, see our RYTM price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $36.67 | Average Broker Recommendation | 1.71 (Moderate Buy) |
RYTM Stock Price Chart Interactive Chart >
RYTM Price/Volume Stats
| Current price | $24.03 | 52-week high | $27.29 |
| Prev. close | $20.86 | 52-week low | $3.04 |
| Day low | $21.20 | Volume | 300,611 |
| Day high | $24.23 | Avg. volume | 1,259,775 |
| 50-day MA | $16.24 | Dividend yield | N/A |
| 200-day MA | $9.86 | Market Cap | 1.22B |
Rhythm Pharmaceuticals, Inc. (RYTM) Company Bio
Rhythm Pharmaceuticals, Inc. develops and commercializes peptide therapeutics for the treatment of rare genetic disorders of obesity in the United States. Its lead product candidate is Setmelanotide, a melanocortin-4 receptor agonist that is in Phase III clinical trials for treating POMC deficiency obesity and leptin receptor deficiency obesity; and Phase II clinical trials for treating Bardet-Biedl syndrome, Alström syndrome, POMC heterozygous deficiency obesity, and POMC epigenetic disorders. The company was founded in 2008 and is based in Boston, Massachusetts.
Latest RYTM News From Around the Web
Below are the latest news stories about RHYTHM PHARMACEUTICALS INC that investors may wish to consider to help them evaluate RYTM as an investment opportunity.
Rhythm Pharmaceuticals to Present at Investor Conferences in SeptemberBOSTON, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) pathway diseases, today announced that Company management will present at three investor conferences in September: 2022 Wells Fargo Healthcare Conference on Thursday, September 8, 2022. David Meeker, M.D., Chair, |
3 Healthcare Stocks That Are Beating the MarketHere's why our roundtable is bullish on Shockwave Medical, Axsome Therapeutics, and Rhythm Pharmaceuticals. |
After Golden Cross, Rhythm Pharmaceuticals, Inc. (RYTM)'s Technical Outlook is BrightGood things could be on the horizon when a stock experiences a golden cross event. How should investors react? |
Rhythm Pharma adds 14% as Goldman upgrades on potential of wight loss agentThe shares of Rhythm Pharmaceuticals (NASDAQ:RYTM) jumped ~14% in the morning hours Monday after Goldman Sachs upgraded the commercial-stage biotech to Buy from Neutral and raised the price target to $28 from $6, citing the potential of its weight loss therapy setmelanotide. Currently, setmelanotide, branded as Imcivree, is indicated in the U.S. for chronic weight management of patients with certain rare genetic diseases of obesity. Last month, Rhythm (Seeking Alpha | August 8, 2022 |
Needham Sticks to Its Buy Rating for Rhythm Pharmaceuticals (RYTM)In a report released today, Joseph Stringer from Needham maintained a Buy rating on Rhythm Pharmaceuticals (RYTM - Research Report), with a price target of $25.00. The company's shares closed last Friday at $20.24.Stringer covers the Healthcare sector, focusing on stocks such as Alnylam Pharma, Rhythm Pharmaceuticals, and Lexicon Pharmaceuticals. According to TipRanks, Stringer has an average return of 0.3% and a 45.18% success rate on recommended stocks. Rhythm Pharmaceuticals has an analyst consensus of Moderate Buy, with a price target consensus of $26.57, which is a 31.27% upside from current levels. In a report released yesterday, Goldman Sachs also upgraded the stock to a Buy with a $28. |
RYTM Price Returns
| 1-mo | 6.09% |
| 3-mo | 563.81% |
| 6-mo | 146.97% |
| 1-year | 87.15% |
| 3-year | 12.08% |
| 5-year | N/A |
| YTD | 140.78% |
| 2021 | -66.43% |
| 2020 | 29.49% |
| 2019 | -14.58% |
| 2018 | -7.50% |
| 2017 | N/A |
Loading social stream, please wait...